An in vitro model for dengue virus infection that exhibits human monocyte infection, multiple cytokine production and dexamethasone immunomodulation

Sônia Regina Nogueira Ignácio Reis, André Luiz Franco Sampaio*, Maria das Graças Muller Henriques*, Mariana Gandini, Elzinandes Leal Azeredo, Claire Fernandes Kubelka/+ Laboratório de Imunologia Viral, Instituto Oswaldo Cruz-Fiocruz *Departamento de Farmacologia Aplicada, Farmanguinhos-Fiocruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brasil

An important cytokine role in dengue fever pathogenesis has been described. These molecules can be associated with haemorrhagic manifestations, coagulation disorders, hypotension and shock, all symptoms implicated in vascular permeability and disease worsening conditions. Several immunological diseases have been treated by cytokine modulation and dexamethasone is utilized clinically to treat pathologies with inflammatory and autoimmune ethiologies. We established an in vitro model with human monocytes infected by dengue virus-2 for evaluating immunomodulatory and antiviral activities of potential pharmaceutical products. Flow cytometry analysis demonstrated significant dengue antigen detection in target cells two days after infection. TNF-α, IFN-α, IL-6 and IL-10 are produced by in vitro infected monocytes and are significantly detected in cell culture supernatants by multiplex microbead immunoassay. Dexamethasone action was tested for the first time for its modulation in dengue infection, presenting optimistic results in both decreasing cell infection rates and inhibiting TNF-α, IFN-α and IL-10 production. This model is proposed for novel drug trials yet to be applied for dengue fever.

Key words: dengue - dexamethasone - monocytes - cytokines - therapeutics

Dengue fever (DF) is an acute infectious viral disease that presents a broad severity spectrum from asymptomatic or oligosymptomatic to extremely severe clinical manifestations. It is believed that immunological mechanisms play a key role in pathogenesis (WHO 1997, Gubler 2002). Proinflammatory cytokines have been associated with haemodynamic and coagulation disorders that may lead to increased vascular permeability and leakage and to hypovolemic shock resulting eventually in death (Green & Rothman 2006). No specific treatment exists for dengue and research has been unsuccessful in finding improved conditions with steroids, antivirals or substances that decrease capillary permeability (Sumarmo et al. 1982, Tassniyom et al. 1993, Pea et al. 2001, Gibbons & Vaughn 2002, Ligon 2005). In patients, fluid-replacement therapy should be administrated according to the severity and paracetamol/metamizole has been prescribed for fever and analgesia.

Glucocorticoids are widely adopted as anti-inflammatory drugs for several inflammatory diseases and are known to suppress of inflammatory mediators expression (Barnes & Adcock 1995, Joyce et al. 1997). Dexamethasone inhibits cytokine gene expression such as TNF-α by blocking transcription factors NF-κB and activator factor-1 (Steer et al. 2000). IL-1β, iNOS, ciclooxigenase-2 and monocyte chemoattractant protein-1 have also been described to destabilize mRNAs during this treatment (Amano et al. 1993, Ristimaki et al. 1996, Poon et al. 1999, Lasa et al. 2001, Korhonen et al. 2002).

Dexamethasone is applied in the clinics to treat pathologies with inflammatory and autoimmune origins, such as rheumatoid arthritis, multiple melanomas and bacterial meningitis (Jimenez-Zepeda & Dominguez-Martinez 2006, van de Beek & de Gans 2006, Schutt et al. 2007) despite some described adverse effects (Stoll et al. 1999, Hempen et al. 2002, Vardy et al. 2006). Reports concerning corticosteroids are yet inconclusive regardin their benefits during DF (Panpanich et al. 2006).

Herein we present an in vitro model with human primary monocytes infected with dengue virus serotype 2 (DENV-2). We evaluated virus load by detecting antigen positive cell rates through flow cytometry and cytokine secretion profile after cell infection by a multiple fluorescent microbead immunoarray. This model is proposed for DF novel drug trials, and dexamethasone was tested for the first time, presenting successful modulation by decreasing infected monocyte frequencies and inhibiting TNF-α, IFN-α and IL-10 production in cell culture supernatants.

MATERIALS AND METHODS

Cell cultures, preparation of virus stock and virus titration - An Aedes albopictus C6/36 cell clone was grown as monolayers at 28°C on Leibovitz medium (L-15)
supplemented with 200 mM glutamine, 1% non-essential amino acids solution, 0.5% tryptose phosphate broth, 100 U/ml penicillin, 10 mg/ml streptomycin and 5% foetal calf serum (FCS). DENV-2 strain 16681 was provided by Dr. Scott B. Halstead (Naval Medical Research Center, USA). The virus was titrated by serial dilution cultures in microtiter plates and detected by immunofluorescence as previously described (Miagostovich et al. 1993). Virus titre was calculated as 50 percent tissue culture infectious dose (TCID50/ml) (Reed & Muench 1938, Schoepf & Beatty 1984). The inactivated virus was prepared by incubating the inoculum for 30 min/56ºC. Titrated virus stock was obtained at a concentration of 5.5 x 10^10 TCID50/ml.

Preparation of human peripheral blood mononuclear leukocytes (PBMLs) - Human peripheral blood was obtained from the Hospital Universitário Clementino Fraga, Rio de Janeiro. Human PBMLs from healthy donors were isolated from buffy coat cells through density gradient centrifugation (350 g/30 min in Ficoll-Paque Plus, Amersham Biosciences Corp) according to standard procedures. Cells were suspended in RPMI 1640 supplemented with 200 mM glutamine, 100 U/ml penicillin and 10 mg/ml streptomycin, afterwards incubated at 37ºC under humid atmosphere with 5% CO2 and allowed to adhere on uncoated polystyrene flasks (150 cm2) during 90 min for monocyte enrichment. Non-adherent cells were removed by washing, and adherent cells were detached by mechanical cell harvestment with cell scrapers in cold cell culture medium, then resuspended in supplemented RPMI plus 10% FBS.

Infection of adherent PBMLs and treatment with dexamethasone - Enriched monocytes suspended in supplemented RPMI 1640 medium plus 10% FCS were seeded at 2 x 10^6 cells/ml on 96 or 24-well plates. After an overnight incubation, infection was performed with inoculum diluted in cell culture medium (30 or 300 µl) containing 2.2 x 10^9 TCID50/ml. After a 2 h-incubation period for adsorption, the cell culture supernatant was replaced with cell culture medium plus 2% FCS and incubated with dexamethasone 0.05 mM at 37°C with 5% CO2. After 48 h, supernatants were collected and stocked at -20ºC until cytokine measurement and cells were resuspended for viral antigen determination by flow cytometry. Cell viability was verified in culture by Trypan blue exclusion and presented ≥ 95% viability. Wells with cell control, inactivated and infectious DENV were assayed.

Cytokine detection in cell culture supernatant by multiplex microbead immunoassay - A multiplex bio-metric immunoassay, containing fluorescent dyed microspheres conjugated with a monoclonal antibody specific for a target protein, was adopted for cytokine measurement according to the manufacturer’s instructions (Upstate), measured cytokines being: IL-1β, IL-6, CXCL8 (IL-8), IL-10, IL-12 (p70), IL-15, IFN-α, and TNF-α. Briefly, cell culture supernatant (50 ml) was incubated overnight with antibody-coupled beads. Complexes were washed and then incubated with biotinylated detection antibody and streptavidin-phycoerythrin prior to assessing cytokine concentration titres, the concentrated human recombinant cytokine provided by the vendor. A broad range 1.95 - 8,000 pg/ml recombinant cytokines was used to establish standard curves as well as maximize assay sensitivity and dynamic range. Cytokine levels were determined using a multiplex array reader from Luminex™ Instrumentation System (Bio-Plex Workstation from Bio-Rad Laboratories). The analyte concentration, calculated with the software from the manufacturer (Bio-Plex Manager Software), provided a regression analysis to derive the equation prediction of the cytokine concentrations in plasma samples.

**Determination of viral antigen by flow cytometry in monocytes** - Adherent monocytes were recovered by scraping with a plastic microtip using cold cell culture medium, then set at 1 x 10^6 cells/microtube, centrifuged (350 g/10 min) and washed once with 1ml phosphate-buffered saline pH 7.4 containing 1% bovine serum albumin with 0.1% NaN3 (PBS/BSA). Cells were fixed with a solution containing 2% paraformaldehyde PBS/BSA at 4°C/20 min and permeabilized with a solution containing 0.15% saponin in PBS/BSA. Permeabilized cells were then blocked with 5% inactivated plasma in PBS/BSA at 4°C/30 min and incubated with mouse anti-dengue complex monoclonal antibody (Chemicon, USA) at 4°C/60 min. Cells were then washed and incubated with anti-mouse IgG labelled with phycoerythrin (DAKO, USA) for 30 min/4°C. After incubation, cells were washed with PBS/BSA and resuspended in 2% paraformaldehyde. Cells were acquired (5,000 events for gated monocytes) on a FACS® Calibur flow cytometer (Beckon & Dickinson, USA) and analysed with FlowJo Software (TreeStar Inc, CA, USA). Isotype-matched antibody was adopted as a staining negative control.

**Statistical analyses** - Data were firstly tested for normality with the GraphPad Prism version 4.02 for Windows, GraphPad™ Software (San Diego, CA, USA, http://www.graphpad.com) in order to determine the significance of differences in DENV antigen positive (DENV-Ag+) cell rates under culture treatment conditions. Data values passed the Kolmogorov-Smirnov normality test and were evaluated for significance using the paired t test (two-tailed). However, the cytokine detection data values obtained by multiplex bead assay did not pass the normality test and was therefore analysed by the non-parametric Wilcoxon matched pairs test (two-tailed). Altered parameters were considered significant at p < 0.05.

**RESULTS**

Human monocytes as an in vitro infection model for DENV: infected cell rates and cytokine production profile - Human monocyte-enriched PBMLs were infected with DENV-2 (strain 16681) and cultured in vitro. In preliminary experiments we searched for DENV-Ag+ cells by flow cytometry analysis (FACS), which indicated that our DENV stock (tested at 2.2 x 10^9 TCID50/ml) induced infection rates peaking on the second day after infection using three different PBML donors (data not shown). Target cells are CD14+ cells (data not shown),
which constitute approximately 95% cells in the mono-
cyte region from cell population size and granularity
(FCS x SSC) dotplots in FACS analysis as described pre-
viously (Neves-Souza et al. 2005).

We also observed that only infectious DENV, but not
heat-inactivated DENV, was effective in DENV-Ag de-
tection (Fig. 1A). Heat-inactivated DENV incubation with
monocytes presented data equivalent to those of cell
culture medium indicating that the antigen detected when
the infectious virus is present might be a result of virus
replication. Infected monocytes from 15 different
PBML donors varied, however DENV-Ag expression was
statistically significant when compared with heat-inac-
tivated DENV (Fig. 1B). Infection rates from the second
day ranged from 10 to 38% total monocytes.

After DENV monocyte infection, cell culture super-
natant was collected and tested for the presence of eight
different cytokines by multiplex microbead immuno-
fluoroscent assay (Luminex™ technology), while the
mock inoculum with heat-inactivated DENV did not
stimulate monocytes cytokine production (Table). In 10-
16 PBML donors tested on the second day after infec-
tion, TNF-α, IL-6, IL-10 and IFN-α were detected at
statistically significant, increased levels when compared
to control monocyte supernatants (Fig. 2). These cytokines
were still present in subsequent days varying their detect-
ion levels, while other cytokines (IL-1β, IL-8, IL-12, and
IL-15) did not alter their levels during seven days in tested
cultures. The two-day time point was determined to
evaluate drug effect for both antiviral and immunomodu-
ulating activities.

Dexamethasone-induced reduction of DENV-Ag+
cell rates on monocytes detected by FACS - Dexam-
ethasone has been reported to be an immunomodulating
agent and experimentally demonstrated to decrease vi-
ral titres, as well as reducing virus-induced inflamma-
tion (Moreno et al. 2003). DENV infected human mono-
cytes from 11 different PBML donors were treated with
dexamethasone for two days in culture. DENV-Ag+ cell
expression was detected by FACS (Fig. 3A) and exhib-
ted a highly significant inhibiting effect on infected cell
frequencies (Fig. 3B). Hence, the dexamethasone effect
results in viral protein downregulation, indicating that virus
particle load is decreased in monocytes after treatment.

Dexamethasone-induced inhibition of cytokine detec-
tion in DENV infected monocyte supernatants - Gluco-
corticoids, such as dexamethasone, inhibit the expression
of inflammatory mediators such as pro-inflammatory
cytokines (Joyce et al. 1997). The dexamethasone
immunomodulating activity was tested on DENV-in-
fected human monocytes cultured for two days. TNF-α,
IL-6, IL-10, and IFN-α were measured in cell superna-
tants from 10-15 different PBML donors with the mul-
tiplex bead immunoassay. Significant TNF-α, IL-10 and
IFN-α inhibition was achieved in treated cultures in con-
trast to untreated (Fig. 4). IL-6 levels in supernatants
from dexamethasone-treated cell cultures were not sta-
tistically different from infected control cultures,
although eight out of 15 PBML donors presented ≥ 35%
IL-6 inhibition rates (total averages: untreated, 1,883 ±
379 and dexamethasone-treated, 1,347 ± 244 pg/ml), five
had unchanged levels and two had ≥ 35% increased
levels. Dexamethasone was acknowledged to be an effec-
tive in vitro treatment to downregulate cytokines pro-
duced during monocyte infection by DENV.

Fig. 1: model for DENV in vitro infection: DENV-Ag detection in mono-
cytes by FACS. Human monocytes were obtained from healthy PBML
donor buffy coats and incubated with cell culture medium, heat-inacti-
vated or infectious DENV-2 (strain 16681). DENV-Ag positive cells were
detected after a 2-days infection by flow cytometry analysis. A: contour
plots represent DENV-Ag+ cells on the monocyte gate. X-axis represents
fluorescence intensity for phycoerythrin (PE) labelling. Quadrants were set as reference to isotype
antibodies; B: box-and-whiskers graph represent data from 15 PBML
donors. The box extends from the 25th to the 75th percentiles, and the
middle line is the median. The error bars, or whiskers, extend down to the
lowest value and up to the highest. Paired t test was used to evaluate
differences between DENV-Ag+ cell rates from heat-inactivated or infec-
tious DENV-cultured monocytes; *** p < 0.05
DISCUSSION

Clinical investigations report an important role for cytokines during DF pathogenesis. Among others, TNF-α, IL-1β, IL-6 and IL-8 have been associated with severity in various studies (Vitarana et al. 1991, Hober et al. 1993, Bethell et al. 1998, Raghupathy et al. 1998, Braga et al. 2001, Fink et al. 2006). Cytokines can be related to haemorrhagic manifestations (Azeredo et al. 2001), coagulation activation, fibrinolysis (Suharti et al. 2002) and may be implicated in vascular permeability and worsening morbidity (Green & Rothman 2006). These conditions are most striking in severe patients, nevertheless may appear during mild disease as well (Avila-Aguero et al. 2004, Nguyen et al. 2004).

Several target cells have been designated by different investigators to perform DENV infection studies in vitro. Mononuclear phagocytes, such as dendritic cells and monocytes, have been appointed as relevant cells for infection both in vitro and in vivo (Scott et al. 1980, Hotta et al. 1984, Halstead 1988, Wu et al. 2000). Circulating peripheral monocytes from patients during the acute phase present DENV-Ags indicating their role during...
natural infection in DF (Neves-Souza et al. 2005). Here we present an in vitro model that detects DENV positive cell frequencies in human primary monocytes and four different cytokines, which are participating in disease development. We demonstrated that after in vitro intervention with dexamethasone this model is successfully modulated for DENV-Ag expression and cytokine production.

**TABLE**

| Cytokine production by infected monocytes compared to mock-infected cells |
|-----------------------------|-----------------|-----------------|
| Control | Inactivated | DENV |
| TNF-α (pg/ml) | 2 ± 1 | 2 ± 0 | 68 ± 5 |
| IL-10 (pg/ml) | 16 ± 11 | 21 ± 10 | 389 ± 145 |
| IFN-α (pg/ml) | 28 ± 8 | 36 ± 6 | 189 ± 118 |
| IL-6 (pg/ml) | 144 ± 119 | 197 ± 71 | 682 ± 207 |

*a*: human monocytes were obtained from healthy PBML donor buffy coats and infected cell culture medium, heat-inactivated or infectious DENV-2 (strain 16681). Cytokine concentration produced in cell culture supernatants was measured simultaneously by multiplex microbead immunoassay. Data represent average ± standard error from 15 PBML donors.

**Fig. 3:** dexamethasone effect on DENV in vitro infection in monocytes. DENV-2 infected human monocytes were incubated with dexamethasone during 2 days. Inhibitory activity against DENV-2 was detected by viral antigen (DENV-Ag) reduced rates in treated monocytes after flow cytometry analysis. A: contour plots represent DENV-Ag+ cells on the monocyte gate. Mean fluorescence intensity (m.f.i.) for the DENV-Ag+ quadrants is shown. The X-axis represents mean of cell population size (FCS) and the Y-axis represents fluorescence intensity for phycoerythrin (PE) labelling. Quadrants were set as reference to isotype antibodies; B: the box-and-whiskers graph represents data from 11 PBML donors. The paired t test was used to evaluate differences between cytokine concentration produced by uninfected and DENV-infected monocytes; * p < 0.05.

**Fig. 4:** dexamethasone effect on cytokine levels produced by DENV infection in monocytes. DENV-2 infected human monocytes were incubated with dexamethasone during 2 days. The box-and-whiskers graph represents data from 10-15 PBML donors. The Wilcoxon matched pairs test was used to evaluate differences between cytokine concentration produced in cell culture supernatants by non-treated and dexamethasone-treated DENV-infected monocytes. Cytokines were measured simultaneously by multiplex microbead immunoassay; * p < 0.05.
and Wang’s report, we can speculate that differences in cytokine production may be related to target cell origin and that monocytes may change their cytokine production after in vitro differentiation. In addition, cytokine genetic polymorphism may also explain these differences considering that the former study was performed in Southeast Asia, in contrast to our South American population, which corroborates the evidence that DF profiles change among several geographic/ethnic regions (Moraes et al. 2006).

Some authors (Chareonsirisuthigul et al. 2007) have exhibited the simultaneous production of several cytokines after DENV infection as herein delineated, but their target cells were derived from a transformed cell line, not primary isolated monocytes. We describe for the first time the dexamethasone inhibitory effects for both DENV-induced cytokine production and virus load reduction on monocytes. There have been several reports of in vitro DENV infection inhibition by different treatments, but human monocytes or other primary cells were not described as targets in these earlier studies. Some treatments inhibited the glycan-processing enzyme endoplasmic-reticular glycosidase and the morphogenesis of viruses that bud from the endoplasmic reticulum (Gu et al. 2007). Others, such as the virus inhibitor ribavirin, act on the enzyme IMP dehydrogenase (IMPDH) that catalyzes the de novo biosynthesis of guanine nucleotides affecting dengue replication (Markland et al. 2000). It is still unknown whether or not the antiviral effect observed here is a direct effect on virus replication steps or an indirect effect stimulating antiviral cytokines/factors.

We demonstrated a novel inhibitory effect induced by dexamethasone that has a striking impact on TNF-α, IFN-α and IL-10 production in human monocyte cultures after DENV-2 infection. This drug is known for its modulating activity on TNF-α production and NF-κB nuclear translocation, which is an essential step for TNF-α induction on stimulated monocytes (Steer et al. 2000). We suggest that NF-κB may exert as well an activation function on TNF-α synthesis after DENV infection and may be one target for dexamethasone. IL-1β (Jeon et al. 2000), IL-6 (Amano et al. 1993), and IL-10 (Bessler et al. 2001) are inhibited by dexamethasone after monocyte induction by LPS, a bacterial product involved in septic shock. Contrastingly, IL-6 is induced during DENV in vitro infection, but dexamethasone does not change significantly its levels in culture. This lack of effect on IL-6 by dexamethasone may be undermined due to the evidence that no important role was found for IL-6 in Brazilian patient severity during recent epidemics (unpublished observations). Other cytokines were also associated with severity, such as IL-18 and TGF-β (Azeredo et al. 2006), and the dexamethasone effect deserves to be studied for these factors as well.

We observed IFN-α downregulation, which may represent an effective immunomodulatory procedure by dexamethasone. This effect is not interfering with virus clearance which can be explained by the antiviral effect from other molecules such as nicotin oxide, known to control DENV replication in monocytes (Neves-Souza et al. 2005, Chareonsirisuthigul et al. 2007). IL-10 is known for its blocking effect on STAT-1 and IRF-1 (Mahalingam & Lidbury 2002), relevant factors for iNOS activation (Dell’Albani et al. 2001), and its expression during DENV infection may result in enzyme inhibition together with reduced nitric oxide effect on DENV replication. After IL-10 downregulation by dexamethasone, iNOS activation may occur, generating nitric oxide that would more efficiently exert its antiviral effects on monocytes. We can not rule out that the antiviral effect was induced by the drug direct interference on virus replication or that cytokine downregulation may be a result from less intense monocyte activation by the virus. Further investigation on these mechanisms deserve to be performed.

One must be aware of adverse effects described in clinical immunotherapeutic procedures during some severe infectious diseases (Hempen et al. 2002, Vardy et al. 2006). Although dexamethasone presented very interesting effects on the in vitro dengue infection model described here, there is insufficient clinical evidence to justify the use of corticosteroids in managing dengue shock syndrome. A recent report evaluates death, blood transfusion need, convulsions and pulmonary haemorrhage concluding that there was no overall benefit attributed to corticosteroids, but the number of participants in the analysis was small (Panpanich et al. 2006).

We believe that this model will be useful to track new substances with therapeutic properties, however further investigations will be mandatory in order to achieve a safe immunomodulatory intervention in which pro-inflammatory factors will be downregulated to a moderate level still enabling virus replication control. This would result in more efficient restoration of host homeostasis, ultimately consummating in avoidance of the most deleterious clinical manifestations during DF.

ACKNOWLEDGEMENTS

To Dr. Jussara P. Nascimento (In memoriam) for her constant encouragement. To the technical support of Alessandro Souza, Maryrose Lavatori, and Mariana Lopes. To Mitchell Raymond Lishon for reviewing the manuscript.

REFERENCES


Azeredo EL, Zagne SMO, Alvarenga AR, Nogueira RMR, Kubelka CF, Oliveira-Pinto LM de 2006. Activated peripheral lymphocytes with increased expression of cell adhesion molecules and cytotoxic markers are associated with dengue fever disease. Mem Inst Oswaldo Cruz 101: 437-449.


